Update on biologic and small molecules treatments in pediatric allergic diseases
Authors:
- Herman T. Den DekkerHDHerman T. Den Dekker
- Amandine Divaret ChauveauACAmandine Divaret Chauveau
- Benoit SterlingBSBenoit Sterling
- Stéphanie CoopmanSCStéphanie Coopman
- R. Sharon ChinthrajahRCR. Sharon Chinthrajah
- Stéphanie LejeuneSLStéphanie Lejeune
- Dorothea HolterDHDorothea Holter
- Thomas EiweggerTEThomas Eiwegger
- Mariëlle W. PijnenburgMPMariëlle W. Pijnenburg
- Antoine DeschildreADAntoine Deschildre
Open Access
- 25 September 2026
- journal article
- review article
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 37 (9) , e70454
Abstract
Biologics have revolutionized the treatment of severe allergic diseases in children that cannot be controlled by conventional treatments. These diseases are commonly driven by dysregulation of immune response, often driven by Type 2 pathways. By targeting them, biologics have the potential for treating one or more allergic diseases. Thus, a “treat to target” strategy is now prioritized, allowing treatment of allergic diseases in a personalized approach. The pioneer anti‐IgE monoclonal antibody, omalizumab, was initially indicated for the treatment of moderate to severe allergic asthma and is now indicated for chronic spontaneous urticaria (CSU), chronic rhinosinusitis with nasal polyps (CRSwNP), and food allergy (FA), highlighting the ability of biologics to target multiple allergic diseases. Other biologics have been developed in asthma and other allergic diseases, including mepolizumab (anti‐IL5), benralizumab (anti‐IL5 receptor), dupilumab (anti–IL‐4 receptor α), and more recently tezepelumab (anti‐TSLP). Clinical trials in children and/or teenagers have demonstrated their efficacy and safety, confirmed by real‐life studies, in asthma, atopic dermatitis (AD), CSU, and more recently in eosinophilic esophagitis (EoE) and FA. Beyond biologics, small molecules such as Janus kinase inhibitors target other key pathways and have already been approved in AD, with ongoing clinical trials in other allergic diseases. In the pediatric specific context, these treatments raise questions, particularly regarding the choice of biologics and the goals. In the long term, the sustained efficacy, safety and impact on the natural history of allergic diseases need to be further studied. The aim of this review is to discuss the most recent data in the use of biologics and small molecules in pediatric allergic diseases and to highlight the remaining gaps in knowledge.Keywords
This publication has 158 references indexed in Scilit:
- Efficacy and Safety of Dupilumab in Children With Moderate‐to‐Severe Asthma: A Systematic Review of Emerging Phase 3 EvidencePediatric Pulmonology, 2025
- Ivarmacitinib for Moderate to Severe Atopic Dermatitis in Adults and AdolescentsJAMA Dermatology, 2025
- Upadacitinib in Adolescents With Moderate to Severe Atopic DermatitisJAMA Dermatology, 2024
- Diagnosis and management of eosinophilic esophagitis in children: An update from the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN)Journal of Pediatric Gastroenterology and Nutrition, 2024
- Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 StudyDermatology and Therapy, 2023
- Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic DermatitisJAMA Dermatology, 2023
- Omalizumab effectiveness in patients with a previously failed oral immunotherapy for severe milk allergyImmunity, Inflammation and Disease, 2021
- Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic DermatitisJAMA Dermatology, 2021
- Omalizumab dampens type 2 inflammation in a group of long‐term treated asthma patients and detaches IgE from FcεRIEuropean Journal of Immunology, 2018
- Impact of omalizumab in children from a middle‐income country with severe therapy‐resistant asthma: A real‐life studyPediatric Pulmonology, 2017